Oxygen Single Bonded To A Ring Carbon Of The Cyclopentanohydrophenanthrene Ring System Patents (Class 514/182)
  • Patent number: 11111266
    Abstract: Compounds are provided according to Formula (A): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R1, R2, R3, R4, R5, R6, and RG are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.
    Type: Grant
    Filed: October 18, 2017
    Date of Patent: September 7, 2021
    Assignee: SAGE THERAPEUTICS, INC.
    Inventors: Francesco G. Salituro, Albert Jean Robichaud, Gabriel Martinez Botella, Boyd L. Harrison, Andrew Griffin
  • Patent number: 11077122
    Abstract: The present invention relates to the use of non-bioconvertible C3-substituted pregnenolone derivatives of formula (I), with no significant affinity for hormonal receptors or receptors of the central nervous system, in the treatment of substance use disorders, and in particular of alcohol use disorder.
    Type: Grant
    Filed: November 4, 2016
    Date of Patent: August 3, 2021
    Assignee: MAPREG
    Inventors: George F. Koob, Barbara Jean Mason, Olivier George, Etienne Baulieu, Isabelle Villey
  • Patent number: 11072631
    Abstract: The present invention relates to methods and novel intermediates useful in the preparation of a compound of formula (A) or a pharmaceutically acceptable salt thereof, comprising converting the aldehyde of a compound of formula (B) with a reducing agent to prepare a compound of formula (C) and converting the compound of formula (C) with a sulfating reagent to prepare a compound of formula (A). An objective of the present invention is to provide methods of preparing bile acid derivatives and novel intermediates. A use of the methods and intermediates described relates to the synthesis of bile acid derivatives which activate both FXR and TGR5.
    Type: Grant
    Filed: September 23, 2016
    Date of Patent: July 27, 2021
    Assignee: Intercept Pharmaceuticals, Inc.
    Inventors: Kevin Schaab, Paul E. Whitley, Flavio Chavez Lopez, Kayla R. Iorga
  • Patent number: 10953115
    Abstract: The invention refers to a process for preparing sterile active pharmaceutical ingredients (APIs) useful in the preparation of sterile product for ophthalmic use. The process comprises the gamma-ray sterilization treatment of the APIs powder in a protective atmosphere.
    Type: Grant
    Filed: May 9, 2012
    Date of Patent: March 23, 2021
    Assignee: Icrom S.R.L.
    Inventors: Mario Leone, Pierfrancesco Morosini
  • Patent number: 10869875
    Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds which inhibit Hedgehog signaling. Also described herein are methods for using such Hedgehog signaling inhibitors, alone or in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of Hedgehog signaling.
    Type: Grant
    Filed: October 25, 2016
    Date of Patent: December 22, 2020
    Assignee: MAX BIOPHARMA, INC.
    Inventors: Frank Stappenbeck, Yi Chiao Fan, Feng Wang, Farhad Parhami
  • Patent number: 10864248
    Abstract: Compositions and kits including an agent that inhibits the interaction between Disabled-2 and mutant CFTR proteins, optionally in combination with a CFTR corrector, CFTR potentiator, CAL inhibitor, mucolytic, anti-inflammatory agent or a combination thereof are provided as are methods for preventing or treating cystic fibrosis.
    Type: Grant
    Filed: November 11, 2015
    Date of Patent: December 15, 2020
    Assignee: TRUSTEES OF DARTMOUTH COLLEGE
    Inventor: Dean R. Madden
  • Patent number: 10858387
    Abstract: The present invention provides a process for preparation of deoxycholic acid or salt thereof; the process comprises the steps of reacting the compound of formula II to obtain a compound of formula III; the compound of formula III is converted to a compound of formula IV and the compound of formula IV is converted to deoxycholic acid. The present invention also provides a process for the purification of deoxycholic acid or salt thereof.
    Type: Grant
    Filed: May 21, 2018
    Date of Patent: December 8, 2020
    Assignee: GLENMARK LIFE SCIENCES LIMITED
    Inventors: Ranjeet Nair, Shekhar Bhaskar Bhirud, Nandkumar Gaikwad, Sharad R. Gore, Rajendra C. Jagdhane, Sandip Gadge, Sukumar Sinha
  • Patent number: 10842884
    Abstract: Compounds of formula (I), wherein Ar is an aryl group optionally further substituted with one or more groups R3; A is a lipophilic, hydrophobic moiety; R1 is a phosphodiester, phosphotriester, thioether or amide group; X is an unsubstituted or substituted C6 to C24 alkylene or alkenylene group, which is optionally interrupted by one or more —NR9—, —O— or —S— linkages, R2 is —YC(R4)(R5)CO2R6; and pharmaceutically acceptable salts or solvates thereof are useful as endosomolytic agents particularly for the delivery of nucleic acids useful in gene therapy.
    Type: Grant
    Filed: September 27, 2017
    Date of Patent: November 24, 2020
    Assignee: UCB Biopharma SRL
    Inventors: Terence Seward Baker, Michael Anthony William Eaton, Timothy John Norman, James Petrie Turner
  • Patent number: 10828283
    Abstract: Methods of reducing hepatitis delta virus (HDV) viral loads in a patient are provided. In some embodiments, the method comprises treating the patient with lonafarnib-ritonavir co-therapy. In some embodiments, the method further comprises treating the patient with an interferon.
    Type: Grant
    Filed: August 1, 2018
    Date of Patent: November 10, 2020
    Assignee: Eiger Biopharmaceuticals, Inc.
    Inventors: David A. Cory, Ingrid Choong, Jeffrey S. Glenn
  • Patent number: 10815267
    Abstract: The present application provides Compound 1: or a pharmaceutically acceptable salt or amino acid conjugate thereof. The present invention relates to an FXR activator and to methods of making and using said compound.
    Type: Grant
    Filed: March 7, 2017
    Date of Patent: October 27, 2020
    Assignee: Intercept Pharmaceuticals, Inc.
    Inventors: Roberto Pellicciari, Antimo Gioiello
  • Patent number: 10799446
    Abstract: A topical application formulation of estrogen and estrogen analogs or other estrogen receptor modulators is disclosed for the treatment of primary or secondary dry eye syndrome (also known as keratoconjunctivitis sicca (KCS)). Preferred formulations include 17-?-estradiol and its derivatives in lipid, liposomes, polymers, or aqueous or non-aqueous vehicles for the topical treatment of the ocular surface tissues particularly as time-release or micro-dose formulations. These formulations may also be useful in treating other conditions where KCS may occur, such as post-operative refractive surgery and corneal transplant patients.
    Type: Grant
    Filed: May 21, 2018
    Date of Patent: October 13, 2020
    Assignee: REDWOOD PHARMA AB
    Inventors: Clive H. Reading, Thomas Rowe, Mario G. Fsadni, Richard Coulon
  • Patent number: 10800807
    Abstract: The application relates to compounds of formula A: or a salt, solvate, ester, tautomer, amino acid conjugate, or metabolite thereof. The compounds of formula A are TGR5 modulators useful for the treatment of various diseases, including metabolic disease, inflammatory disease, autoimmune disease, cardiac disease, kidney disease, cancer, and gastrointestinal disease.
    Type: Grant
    Filed: June 16, 2016
    Date of Patent: October 13, 2020
    Assignee: Intercept Pharmaceuticals, Inc.
    Inventors: Roberto Pellicciari, Antimo Gioiello, Antonio Macchiarulo, Francoise Perron-Sierra, Klaus Seedorf
  • Patent number: 10765685
    Abstract: Compounds are provided according to Formula (I): Formula (I) and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, wherein R1, R2, R3, R6, R7, R8, and n are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: September 8, 2020
    Assignee: Sage Therapeutics, Inc.
    Inventors: Francesco G. Salituro, Albert Jean Robichaud, Gabriel Martinez Botella
  • Patent number: 10758549
    Abstract: The disclosure relates to obeticholic acid formulations with improved stability, dissolution, and/or solubility, methods of preparing the same for use and methods of treating various diseases and conditions.
    Type: Grant
    Filed: February 11, 2020
    Date of Patent: September 1, 2020
    Assignee: Intercept Pharmaceuticals, Inc.
    Inventors: Richard Gail Lancaster, Kay K. Olmstead, Masashi Kagihiro, Mitsuhiro Matono, Ikuko Taoka, Mark Pruzanski, David Shapiro, Roya Hooshmand-Rad, Richard Pencek, Cathi Sciacca, Lise Eliot, Jeffrey Edwards, Leigh A. MacConell, Tonya K. Marmon
  • Patent number: 10676500
    Abstract: The present invention relates to processes for preparing compounds of Formula (I) and compounds of Formula (II): These compounds are useful as FXR or TGR5 modulators.
    Type: Grant
    Filed: April 9, 2018
    Date of Patent: June 9, 2020
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Guoqiang Wang, Yong He, Brett Granger, Xuechao Xing, Yat Sun Or
  • Patent number: 10668123
    Abstract: Capsicum compositions are described that include biologically active constituents non-capsaicinoids and capsaicinoids in a specific ratio are useful for the treatment and management of cardiometabolic syndrome and associated risk factors, in a subject in need thereof. The capsicum compositions include a capsicum extract which is prepared by extracting capsicum pods by using suitable polar and non-polar solvents. Capsicum compositions include non-capsaicinoid components like saponins and polyphenols such as flavonoids, which along with capsaicinoids effectively reduce risk factors of cardiometabolic syndrome and also reduce oxidative stress on vital body organs by reducing inflammatory and/or oxidative markers. The capsicum compositions inhibit pancreatic lipase enzyme and enhance lipolysis, when administered in an effective amount to a subject in need thereof. Capsicum compositions as described herein are prepared by human intervention and are safe for consumption.
    Type: Grant
    Filed: April 27, 2016
    Date of Patent: June 2, 2020
    Assignee: OmniActive Health Technologies Limited
    Inventors: Jayant Deshpande, Vijaya Juturu, Khadija Ghanam, Vandita Srivastava, Jyotish Srivastava, Sudhakar Akella
  • Patent number: 10654834
    Abstract: The present invention relates to tricyclic compounds of formula (I) and formula (II), or a pharmaceutically acceptable salt thereof. The present tricyclic compounds are useful non-systemic TGR5 agonists that can be used to treat diabetic diseases in human. The present invention provides a pharmaceutical composition containing tricyclic compounds of formula (I) and formula (II) and a method of making as well as a method of using same in treating patients inflicted with metabolic disorders by administering same. The compounds of the present invention may be used in combination with additional anti-diabetic drugs.
    Type: Grant
    Filed: June 29, 2017
    Date of Patent: May 19, 2020
    Assignee: Venenum Biodesign, LLC
    Inventors: Chia-Yu Huang, Brian F. McGuinness, Xiaoqing Xu, Steven G. Kultgen, Ellen Sieber McMaster, James R. Beasley
  • Patent number: 10646499
    Abstract: The disclosure relates to obeticholic acid formulations with improved stability, dissolution, and/or solubility, methods of preparing the same for use and methods of treating various diseases and conditions.
    Type: Grant
    Filed: July 9, 2018
    Date of Patent: May 12, 2020
    Assignee: Intercept Pharmaceuticals, Inc.
    Inventors: Richard Gail Lancaster, Kay K. Olmstead, Masashi Kagihiro, Mitsuhiro Matono, Ikuko Taoka, Mark Pruzanski, David Shapiro, Roya Hooshmand-Rad, Richard Pencek, Cathi Sciacca, Lise Eliot, Jeffrey Edwards, Leigh A. MacConell, Tonya K. Marmon
  • Patent number: 10576090
    Abstract: A formulation for drug delivery, providing enhanced modulation of solubility, stability, absorption, metabolism, and/or pharmacokinetic profile of a lipophilic therapeutic agent by formulation with sterols and/or sterol esters, resulting in higher bioavailability of a therapeutic agent administered to a subject in need of such therapeutic agent. The formulation contains a therapeutic agent and a sterol or sterol ester, and can, optionally, further contain a solubilizer and/or an enhancing agent. Also described are pharmaceutical compositions containing the formulations and methods of making and methods of using the formulations and pharmaceutical compositions. Formulations of the disclosure can be constituted to minimize the synthesis of dihydrotestosterone when the therapeutic agent includes testosterone or testosterone esters.
    Type: Grant
    Filed: April 23, 2018
    Date of Patent: March 3, 2020
    Assignee: Marius Pharmaceuticals LLC
    Inventor: Om Dhingra
  • Patent number: 10525065
    Abstract: Method and composition for treating psoriasis and other skin disorders.
    Type: Grant
    Filed: October 10, 2018
    Date of Patent: January 7, 2020
    Assignee: ANAPLASI PHARMACEUTICALS, LLC
    Inventor: Edward Richard Yuhas
  • Patent number: 10519192
    Abstract: The invention relates to compounds, compositions and polymers comprising a first component adapted to promote germination of Clostridium difficile (C.diff) and a second component which acts as an antimicrobial agent. Said compounds, compositions and polymers are useful for destroying C.diff where conventional antimicrobial agents are unsuccessful. The compositions can be formulated as coating or materials which actively destroy C.diff which come into contact with it. The germination promotion is induced by bile salts. The invention also relates to the use of such materials as a treatment for C.diff associated diseases and toxic megacolon.
    Type: Grant
    Filed: November 26, 2015
    Date of Patent: December 31, 2019
    Assignee: INSIGHT HEALTH LIMITED
    Inventors: Daniel Lee Rathbone, Tony Worthington, Sahar Al-Malaika, Matthew Justin Hird, Alexandria Rose Quayle
  • Patent number: 10485809
    Abstract: Polyethylene glycol (PEG)-conjugated glucocorticoid prodrugs, methods of preparation, and use for the treatment of diseases and disorders are disclosed. In particular, PEG-conjugated dexamethasone compounds and methods of using them for treating inflammatory and autoimmune diseases, including but not limited to lupus, are disclosed.
    Type: Grant
    Filed: November 12, 2016
    Date of Patent: November 26, 2019
    Assignee: Board of Regents of the University of Nebraska
    Inventors: Dong Wang, Fang Yuan, Zhenshan Jia, Xiaobei Wang
  • Patent number: 10478505
    Abstract: The present invention relates to the formulation of steroids, including neurosteroids (e.g., allopregnanolone (ALP)) in edible oils to enhance their absorption when administered, e.g., orally or transmucosally to a patient.
    Type: Grant
    Filed: September 21, 2012
    Date of Patent: November 19, 2019
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventor: Michael A. Rogawski
  • Patent number: 10471064
    Abstract: The invention provides a pharmaceutical composition for treating atopic dermatitis of a human that is induced by Herpes simplex virus (HSV), said pharmaceutical composition comprising an effective amount of 2-[(2-amino-6-oxo-6,9-dihydro-3H-purin-9-yl)methoxy]ethyl-2-amino-3-methylbutanoate and an effective amount of an Anti-allergic agent.
    Type: Grant
    Filed: March 7, 2018
    Date of Patent: November 12, 2019
    Inventor: Lily Hsiao
  • Patent number: 10471086
    Abstract: The methods described herein are based on the discovery that the plasma level of a panel of specific proteins differs between two subject populations: 1) subjects at risk for chronic obstructive pulmonary disease (“COPD”) but not manifesting clinical symptoms of COPD; and 2) subjects having very severe COPD. The difference in plasma levels is statistically significant for each protein. The identification of these proteins thus facilitates susceptibility detection, early disease detection, disease severity assessment, disease progression monitoring, and therapy efficacy monitoring.
    Type: Grant
    Filed: March 25, 2016
    Date of Patent: November 12, 2019
    Assignee: Temple University—Of The Commonwealth System Of Higher Education
    Inventors: Salim Merali, Steven G. Kelsen, Carlos A. Barrero
  • Patent number: 10441595
    Abstract: Disclosed herein are methods of treating fungal infections in a patient, comprising identifying a patient in need of treatment and administering a therapeutically effective amount of at least one cationic steroid antimicrobial (CSA), or a pharmaceutically acceptable salt thereof. Kits comprising such compositions and instructions on such methods are also contemplated herein.
    Type: Grant
    Filed: June 25, 2015
    Date of Patent: October 15, 2019
    Assignee: BRIGHAM YOUNG UNIVERSITY
    Inventors: Carl Genberg, Chad S. Beus, Paul B. Savage
  • Patent number: 10434107
    Abstract: Bile acids and related compositions and methods of synthesis and use. More specifically, deoxycholic acid and related compositions, said compositions being free of all moieties of animal origin and free of pyrogenic moieties.
    Type: Grant
    Filed: March 29, 2018
    Date of Patent: October 8, 2019
    Assignee: ALLERGAN SALES, LLC
    Inventors: Robert M. Moriarty, Nathaniel E. David, Nadir Ahmeduddin Mahmood
  • Patent number: 10434108
    Abstract: Bile acids and related compositions and methods of synthesis and use. More specifically, deoxycholic acid and related compositions, said compositions being free of all moieties of animal origin and free of pyrogenic moieties.
    Type: Grant
    Filed: May 23, 2018
    Date of Patent: October 8, 2019
    Assignee: ALLERGAN SALES, LLC
    Inventors: Robert M. Moriarty, Nathaniel E. David, Nadir Ahmeduddin Mahmood
  • Patent number: 10421772
    Abstract: The invention relates to compounds of formula (I): wherein R is ethyl, propyl or allyl, and pharmaceutically acceptable salts, solvates or amino acid conjugates thereof. The compounds of formula (I) are useful as FXR agonists.
    Type: Grant
    Filed: July 10, 2017
    Date of Patent: September 24, 2019
    Assignee: Intercept Pharmaceuticals, Inc.
    Inventor: Roberto Pellicciari
  • Patent number: 10407462
    Abstract: The present invention relates to compounds having cholane scaffolds of formula (I), said compounds for use in the treatment and/or prevention of FXR and TGR5/GPBAR1 mediated diseases.
    Type: Grant
    Filed: May 28, 2015
    Date of Patent: September 10, 2019
    Assignee: BAR PHARMACEUTICALS S.R.L.
    Inventors: Angela Zampella, Stefano Fiorucci
  • Patent number: 10369160
    Abstract: The present invention relates to methods of treating or preventing cancer in a subject in need thereof comprising administering a therapeutically effective amount of a compound of the invention.
    Type: Grant
    Filed: April 11, 2017
    Date of Patent: August 6, 2019
    Assignee: Intercept Pharmaceuticals, Inc.
    Inventors: Antonio Moschetta, Jesus Maria Banales Asurmedi, Luis Bujanda Fernández de Pierola, María Jesús Perugorria Montiel, Oihane Erice Azparren
  • Patent number: 10369159
    Abstract: [Problem] To provide a therapeutic agent for estrogen-dependent gynecological diseases such as endometriosis, uterine fibroids, and uterus adenomyosis. [Solution] To use an estrogen receptor ?-inhibiting ? partial agonist represented by the formula (a), a pharmaceutically-acceptable salt thereof, or a hydrate of either of the afore-mentioned, as an active ingredient.
    Type: Grant
    Filed: September 21, 2018
    Date of Patent: August 6, 2019
    Assignees: Nobelpharma Co., Ltd., National University Corporation Tottori University
    Inventors: Kenichiro Nakao, Tasuku Harada, Fuminori Taniguchi
  • Patent number: 10344049
    Abstract: A compound and pharmaceutically acceptable salts thereof for treating cancer, having a structure represented by the following formula (I) or formula (II): in which X and Y each individually represent: R1, R2, R3, R4, and R5 individually represents hydrogen atom, acyl having 20 or less carbon atoms, alkyl having 20 or less carbon atoms, alkanoyl having 20 or less carbon atoms, aroyl having 20 or less carbon atoms, aryl having 20 or less carbon atoms, aralkyl having 20 or less carbon atoms, sulfonyl having 20 or less carbon atoms, phosphonyl having 20 or less carbon atoms, or haloacyl having 20 or less carbon atoms.
    Type: Grant
    Filed: December 14, 2017
    Date of Patent: July 9, 2019
    Assignee: AQUAVAN TECHNOLOGY CO., LTD
    Inventors: Shi-Yie Cheng, Yao-Ting Wang, Kuo-Tang Tseng, Wen-Hung Chen, Hsin Ju Wang
  • Patent number: 10278977
    Abstract: There is provided a method of treatment of hypersomnolence comprising administering the steroidal compound 3?-ethynyl-3?-hydroxy-5?-androstan-17-one oxime, or a pharmaceutically acceptable salt thereof, to a subject in need of such treatment.
    Type: Grant
    Filed: June 5, 2017
    Date of Patent: May 7, 2019
    Assignee: Umecrine Cognition AB
    Inventors: Torbjörn Bäckström, Magnus Doverskog, Maja Johansson, Pontus Wasling
  • Patent number: 10273263
    Abstract: Various prodrug compounds having the general structure: Active agent—(acid)-(linker)—SO2NR1R2 are described herein. Compounds having this general structure were shown to be more orally active than the unmodified parent molecule.
    Type: Grant
    Filed: August 24, 2017
    Date of Patent: April 30, 2019
    Assignee: Evestra, Inc.
    Inventors: Klaus Nickisch, Bindu Santhamma, Gulzar Ahmed, Frederick Meece, Walter Elger, Ralf Wyrwa, Hareesh Nair
  • Patent number: 10246481
    Abstract: Provided herein, inter alia, are methods for the preparation of modulators of farnesoid X receptor (FXR), and compositions and uses of the modulators of FXR.
    Type: Grant
    Filed: May 18, 2018
    Date of Patent: April 2, 2019
    Assignee: CITY OF HOPE
    Inventors: Donna Yu, Barry Forman
  • Patent number: 10238664
    Abstract: Described are oxysterols, pharmaceutical compositions including the oxysterols, and methods of using the oxysterols and compositions for treating diseases and/or disorders related to myelin injury, such as neonatal brain injury, traumatic brain injury, spinal cord injury, cerebral palsy, seizures, cognitive delay, multiple sclerosis, stroke, autism, leukodystrophy, schizophrenia and bipolar disorder.
    Type: Grant
    Filed: July 9, 2015
    Date of Patent: March 26, 2019
    Assignee: Duke University
    Inventor: Eric J. Benner
  • Patent number: 10231982
    Abstract: This invention relates the use of cortisol blockers (glucocorticoid receptor [GR] antagonists) for the treating or preventing treatment resistant prostate cancer, treating or preventing neoplasia, and treating or preventing infection related to acute or chronic injury or disease.
    Type: Grant
    Filed: July 31, 2018
    Date of Patent: March 19, 2019
    Assignee: Pop Test Oncology Limited Liability Company
    Inventors: Randice Lisa Altschul, Neil David Theise, Myron Rapkin, Rebecca O'Brien
  • Patent number: 10202414
    Abstract: The present invention relates to processes for preparing compounds of formula I or a pharmaceutically acceptable salt or solvate thereof, wherein the dashed bond (----) at position 7 indicates that the substituent is in an ? or ? stereochemistry; R is hydrogen or hydroxy; and R1 is hydrogen or C1-C6 alkyl
    Type: Grant
    Filed: August 21, 2017
    Date of Patent: February 12, 2019
    Assignee: Intercept Pharmaceuticals, Inc.
    Inventors: Roberto Pellicciari, Antimo Gioello
  • Patent number: 10201550
    Abstract: Compounds are provided according to Formula (I): Formula (I) and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R1, R2, R3, R6, R7, R8, and n are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.
    Type: Grant
    Filed: July 6, 2016
    Date of Patent: February 12, 2019
    Assignee: Sage Therapeutics, Inc.
    Inventors: Francesco G. Salituro, Albert Jean Robichaud, Gabriel Martinez Botella
  • Patent number: 10156564
    Abstract: Among the various aspects of the present disclosure is the provision of methods of detecting biomarkers of endoplasmic reticulum (ER) stress-associated kidney diseases. Another aspect of the present disclosure provides for a method of treating an endoplasmic reticulum (ER) stress-associated kidney disease in a subject.
    Type: Grant
    Filed: July 31, 2017
    Date of Patent: December 18, 2018
    Assignee: Washington University
    Inventors: Ying Chen, Yeawon Kim
  • Patent number: 10143938
    Abstract: The present application relates to a method for obtaining a mixture of estrogens from the pregnant mare's urine.
    Type: Grant
    Filed: September 12, 2016
    Date of Patent: December 4, 2018
    Assignee: DR. REDDY'S LABORATORIES LTD.
    Inventors: Chandrashaker Akula, John Lomans, Madhukiran Tummidi, Prashant Anil Tatake
  • Patent number: 10143721
    Abstract: Disclosed are compositions for inhibiting transmission of a sexually transmitted infection that contain one or more polyanionic microbicides, such as carrageenans, including lambda carrageenan, as well as water-soluble metal salts and specified lectins. Also disclosed are methods for making and using the compositions.
    Type: Grant
    Filed: January 13, 2015
    Date of Patent: December 4, 2018
    Assignees: The Population Council, Inc., The United States of America, as represented by the Secretary, Dept. of Health and Human Services
    Inventors: Barry R. O'Keefe, Melissa Robbiani, José A. Fernández Romero
  • Patent number: 10144757
    Abstract: Bile acids and related compositions and methods of synthesis and use. More specifically, deoxycholic acid and related compositions, said compositions being free of all moieties of animal origin and free of pyrogenic moieties.
    Type: Grant
    Filed: June 8, 2017
    Date of Patent: December 4, 2018
    Assignee: Kythera Biopharmaceuticals, Inc.
    Inventors: Robert M. Moriarty, Nathaniel E. David, Nadir Ahmeduddin Mahmood
  • Patent number: 10144759
    Abstract: The sulfated oxysterol 5-cholesten-3?, 25-diol 3-sulphate, a nuclear cholesterol metabolite that decreases lipid biosynthesis and increases cholesterol secretion and degradation, is provided as an agent to lower intracellular and serum cholesterol and/or triglycerides, and to prevent or treat lipid accumulation-associated inflammation and conditions associated with such inflammation. Methods which involve the use of this sulfated oxysterol to treat conditions associated with high cholesterol and/or high triglycerides and/or inflammation (e.g. hypercholesterolemia, hypertriglyceridemia, non-alcoholic fatty liver diseases, atherosclerosis, etc.) are also provided.
    Type: Grant
    Filed: February 12, 2016
    Date of Patent: December 4, 2018
    Assignee: VIRGINIA COMMONWEALTH UNIVERSITY
    Inventors: Shunlin Ren, William M. Pandak
  • Patent number: 10071108
    Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of hepatitis B virus infection. In particular, the present invention relates to farnesoid X receptor (FXR) agonists for use in a method for the treatment of hepatitis B virus infection in a subject in need thereof.
    Type: Grant
    Filed: February 19, 2018
    Date of Patent: September 11, 2018
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE CLAUDE BERNARD—LYON 1, ENS—ECOLE NORMALE SUPÉRIEURE DE LYON, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), EDELRIS, POXEL
    Inventors: Patrice Andre, Vincent Lotteau, Pauline Radreau, Marine Gilardone, Amaury Patin, Didier Roche, Daniel Cravo, Sophie Hallakou-Bozec
  • Patent number: 10064876
    Abstract: Compositions and methods for treating addiction in a subject are disclosed. In particular, compositions and methods for treating addiction to a dopaminergic psychostimulant are disclosed. In some embodiments, addiction is treated by agonizing bile acid receptors in the subject. For example, in some embodiments, the method comprises administering to the subject a therapeutically effective amount of a composition comprising a therapeutically effective amount of a bile acid receptor agonist. In some embodiments, the method comprises surgically diverting bile acids in the subject in a manner suitable to increase circulating bile acids in the subject.
    Type: Grant
    Filed: July 25, 2016
    Date of Patent: September 4, 2018
    Assignee: Vanderbilt University
    Inventors: Aurelio Galli, Heinrich J. G. Matthies, Naji N. Abumrad, India A. Reddy, Charles Robb Flynn, Kevin Erreger
  • Patent number: 9987291
    Abstract: Bile acids and related compositions and methods of synthesis and use. More specifically, deoxycholic acid and related compositions, said compositions being free of all moieties of animal origin and free of pyrogenic moieties.
    Type: Grant
    Filed: March 28, 2017
    Date of Patent: June 5, 2018
    Assignee: Kythera Biopharmaceuticals, Inc.
    Inventors: Robert M. Moriarty, Nathaniel E. David, Nadir Ahmeduddin Mahmood
  • Patent number: 9974866
    Abstract: The present invention provides polymer-polypeptide conjugates comprising a poly(2-oxazoline) amphiphilic block copolymer linked to a polypeptide and methods of use thereof.
    Type: Grant
    Filed: April 7, 2011
    Date of Patent: May 22, 2018
    Assignee: Board of Regents of the University of Nebraska
    Inventors: Alexander V. Kabanov, Jing Tong
  • Patent number: 9949986
    Abstract: Bile acids and related compositions and methods of synthesis and use. More specifically, deoxycholic acid and related compositions, said compositions being free of all moieties of animal origin and free of pyrogenic moieties.
    Type: Grant
    Filed: November 11, 2016
    Date of Patent: April 24, 2018
    Assignee: Kythera Biopharmaceuticals, Inc.
    Inventors: Robert M. Moriarty, Nathaniel E. David, Nadir Ahmeduddin Mahmood